Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1

<p>Background and Aims</p> <p>Little is known about genetic factors that affect development of alcohol-related cirrhosis. We performed a genome-wide association study (GWAS) of samples from the United Kingdom Biobank (UKB) to identify polymorphisms associated with risk of alcohol-r...

Full description

Bibliographic Details
Main Authors: Innes, H, Buch, S, Hutchinson, S, Guha, IN, Morling, JR, Barnes, E, Irving, W, Forrest, E, Pedergnan, V, Goldberg, D, Aspinall, E, Barclay, S, Hayes, P, Dillon, J, Nischalke, HD, Lutz, P, Spengler, U, Fischer, J, Berg, T, Brosch, M, Eyer, F, Datz, C, Mueller, S, Peccerella, T, Deltenre, P, Marot, A, Soyka, M, McQuillin, A, Morgan, MY, Hampe, J, Stickel, F
Format: Journal article
Language:English
Published: American Gastroenterological Association 2020
Description
Summary:<p>Background and Aims</p> <p>Little is known about genetic factors that affect development of alcohol-related cirrhosis. We performed a genome-wide association study (GWAS) of samples from the United Kingdom Biobank (UKB) to identify polymorphisms associated with risk of alcohol-related liver disease.</p> <br> <p>Methods</p> <p>We performed a GWAS of 35,839 participants in the UKB with high intake of alcohol against markers of hepatic fibrosis (FIB-4, APRI, and Forns index scores) and hepatocellular injury (levels of aminotransferases). Loci identified in the discovery analysis were tested for their association with alcohol-related cirrhosis in 3 separate European cohorts (phase 1 validation cohort; n=2545). Variants associated with alcohol-related cirrhosis in the validation at a false discovery rate of less than 20% were then directly genotyped in 2 additional European validation cohorts (phase 2 validation, n=2068).</p> <br> <p>Results</p> <p>In the GWAS of the discovery cohort, we identified 50 independent risk loci with genome-wide significance ( P < 5 × 10 −8). Nine of these loci were significantly associated with alcohol-related cirrhosis in the phase 1 validation cohort; 6 of these 9 loci were significantly associated with alcohol-related cirrhosis in phase 2 validation cohort, at a false discovery rate below 5%. The loci included variants in the mitochondrial amidoxime reducing component 1 gene ( MARC1) and the heterogeneous nuclear ribonucleoprotein U like 1 gene ( HNRNPUL1). After we adjusted for age, sex, body mass index, and type-2 diabetes in the phase 2 validation cohort, the minor A allele of MARC1:rs2642438 was associated with reduced risk of alcohol-related cirrhosis (adjusted odds ratio, 0.76; P=.0027); conversely, the minor C allele of HNRNPUL1:rs15052 was associated with an increased risk of alcohol-related cirrhosis (adjusted odds ratio, 1.30; P=.020).</p> <br> <p>Conclusions</p> <p>In a GWAS of samples from the UKB, we identified and validated (in 5 European cohorts) single-nucleotide polymorphisms that affect risk of alcohol-related cirrhosis in opposite directions: the minor A allele in MARC1:rs2642438 decreases risk, whereas the minor C allele in HNRNPUL1:rs15052 increases risk.</p>